Clinical Measure Baseline 12 Months Change* P
A1C, mean (SD) (N=218) 8.19(0.94) 7.41 (1.22) -0.78(1.16) <0.01
A1C, % (N=218)        
≤6.5%**   23.4    
<7.0%**   39.9    
<7.5% 20.6 59.6 39.0.8 <0.01
         
Weight (kg), mean (SD) (N=209) 101.3(18.8) 98.2(18.6) -3.1 (5.7) <0.01
      -0.03 (0.1)*** <0.01
Lipids mg/dl        
Cholesterol, mean (SD) (N=115) 168.9(41.1) 154.2(30.8) -10.7(35.0) <0.01
HDL, mean (SD) (N=112) 42.4(11.1) 43.0(10.9) 0.6(5.8) 0.25
Blood pressure mm Hg (N=208)        
SBP, mean (SD) 131.2(14.8) 129.1(13.3) -2.1(17.2) 0.08
DBP, mean (SD) 73.7(8.8) 72.3(9.2) -1.4(9.4) 0.03
Table 3: Liraglutide clinical measures at baseline and 12 months; *Changes shown are absolute (12-month value minus baseline value) unless otherwise noted. **Patients were included in the study only if baseline A1C was greater than 7%. ***Relative change (=absolute change divided by baseline value). Note: Data expressed as mean (standard deviation) unless otherwise noted. HDL, high density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.